Identifying nutritional, functional, and quality of life correlates with male hypogonadism in advanced cancer patients

Domenico Fuoco\textsuperscript{1, 4}, Jonathan di Tomasso\textsuperscript{4}, Caroline Boulos\textsuperscript{1}, Robert D Kilgour\textsuperscript{5, 2}, Jose A Morais\textsuperscript{1, 3}, Manuel Borod\textsuperscript{1, 4} and Antonio Vigano\textsuperscript{1, 4}

\textsuperscript{1}McGill Nutrition and Performance Laboratory, McGill University Health Centre, Montreal H4A 3S5, Canada
\textsuperscript{2}Department of Exercise Science, Concordia University, Montreal H4B 1R6, Canada
\textsuperscript{3}Department of Geriatric Medicine, McGill University, Montreal H4A 3S5, Canada
\textsuperscript{4}Division of Supportive and Palliative Care Medicine, McGill University Health Centre, Montreal H4A 3S5, Canada

Correspondence to: Antonio Vigano. Email: antonio.vigano@mcgill.ca

Abstract

With the availability of a potential treatment to reverse male hypogonadism (MH), the primary aim of this case series study was to determine independent relationships between this condition and the nutritional, functional, and quality of life characteristics of advanced cancer patients (ACP). Free testosterone levels were measured in 100 male patients with advanced lung and gastrointestinal (GI) cancer. Routine blood markers of nutrition and inflammation, self-reporting questionnaires for symptom, nutrition, and functional status along with handgrip dynamometry were assessed for all patients at bedside. Almost half of this cohort underwent further assessments (body composition, lower body strength, in depth quality of life and fatigue questionnaires) at the McGill Nutrition and Performance Laboratory (mnupal.mcgill.ca). Multiple regression analyses were performed to identify independent correlations between free testosterone and the above measures. Seventy-six percent of patients were diagnosed with MH. Using multiple linear regression, low free testosterone (31.2 pmol/L) was independently associated with lower albumin (B = –3.8 g/L; 95% confidence interval CI –6.8:–0.8), muscle strength (–11.7 lbs; –20.4: –3.0) and mass in upper limbs (–0.8 kg; –1.4: –0.1), overall performance status (Eastern Cooperative Oncology Group Performance Scale, ECOG PS 0.6; 0.1:1.1), cancer-related fatigue (Brief Fatigue Inventory, BFI 16.7; 2.0: 31.3), and overall quality of life (MQoL total score –1.42; –2.5: –0.3). Thus MH seems to be highly prevalent in ACP, and it is independently associated with important nutritional, functional, and quality of life characteristics in this patient population.

Keywords: hypogonadism, male, quality of life, function, testosterone, cachexia, cancer, case series study
Introduction

MH is characterised by the presence of low circulating concentrations of androgens, namely testosterone, a hormone mainly produced by the testicles [1]. Androgen deficiency has been found to be highly prevalent in male cancers and it has been suggested as a contributing factor of cachexia sequela and cancer-related fatigue [2]. In addition, MH could be an important cause of muscle wasting in cancer cachexia and sarcopenia [2]. Clinical signs such as high levels of inflammation, low appendicular fat and muscle mass, and questionnaire scores indicative of anxiety, depression, and poor functional well-being, have been found to be associated with MH primarily via univariate analyses [2]. Recently, Dev et al (2014) confirmed the association between MH and survival through multivariate analyses [3]. The aim of this case series study is to determine, using multivariate analyses, whether independent relationships exist between MH and nutritional, functional, and quality of life characteristics in ACP.

Methods

Population

The work herein discusses a clinical study classified according to the National Cancer Institute (NCI) in consecutive case series. All patients recruited for this study were male and had a new diagnosis (six months or less) of advanced (stage III–IV) GI or non-small cell lung (NSCL) cancers within the Cancer Mission of the McGill University Health Centre. The patient recruitment and data collection took place between March 2006 and November 2007. Ethical approval was acquired from the Institutional Review Board of the McGill University Health Centre.

Measures

The diagnosis of MH was made on the basis of serum-free testosterone measurement, using the Coat-A-Count (Diagnostic Product Corp., Los Angeles, CA) radioimmunoassay, and ADAM questionnaire [12]. Concentrations lower than 31.2 pmol/L were considered to be clinically significant for MH, as already reported by Gagnon et al [7].

All other assessments took place either in the hospital setting (at bedside or in outpatient clinics) or at the McGill Nutrition and Performance Laboratory (MNUPAL, www.mnupal.mcgill.ca). MNUPAL is a clinical outcome research laboratory where patients affected by multiple chronic diseases such as cancer in advanced stages can receive the best supportive care and medical oversight in a new state-of-the-art facility. In the hospital setting, the following tests were completed: the Edmonton Symptom Assessment System (ESAS) to assess severity of anorexia, weakness, dyspnoea, and decreased feeling of well-being; the abridged Patient Generated Subjective-Global Assessment (aPG-SGA) to evaluate nutritional status; and handgrip strength by Jamar dynamometry (Sammons Preston, Bolingbrook, IL). Selected blood markers were also measured to assess the presence/severity of the inflammatory response (white blood cells count, C-reactive protein) and visceral protein status (serum albumin).

At MNUPAL, the patients completed the BFI [22] and the McGill Quality of Life questionnaire (MQoL) [23]. Body composition was assessed via dual-energy x-ray absorptiometry (DXA) (Lunar Prodigy, GE Healthcare, Madison, WI). Scans were analysed for total lean and fat mass (kg), percentage of fat and appendicular lean tissues, along with bone mineral content and bone mineral density, using the Advance Encore software (GE Healthcare).

All data was stored in the MNUPAL Human Cancer Cachexia Database (HCCD).

Statistical analysis

In order to test for independent relationships between low free testosterone levels (independent variable) with the above clinical and biological outcomes (dependent variables), we performed several multivariate linear regression models (one for each dependent variable), controlling for gender, age, time between diagnosis, and baseline assessment, survival time from baseline assessments to death/loss to follow-up, diagnosis of lung versus GI malignancies, presence/absence of concurrent oncological treatment (radio/chemotherapy), and
Results and discussion

Results

At the time of the final analysis, 100 patients satisfied the inclusion criteria and were recruited for this study. All patients were assessed at the hospital bedside, whereas 48 of them (48%) were also assessed at the MNUPAL. Table 1 indicates the clinical characteristics (n = 100). Patients had an average age of 64 years old (SD ± 11.5) and presented predominantly with GI malignancies (62%). The presence of MH was identified in 76 patients (76%). A statistically significant indirect association was found between MH and albumin levels (p = 0.01). MH was also associated with higher levels of fatigue, poor performance status, and quality of life. Significantly lower handgrip strength correlated with MH as well as decreased muscle mass in the upper limbs. However, there was no statistically significant relationship between MH and symptom severity or biological markers of inflammation (p > 0.2).

Discussion

The study shows that in a sample of 100 patients, there is a high prevalence of hypogonadism in males with advanced cancer. In addition, there is an independent relationship between MH and a worsening of visceral protein status, muscle strength, and mass in upper limbs, overall performance status, cancer-related fatigue, functional, and overall quality of life.

According to Burney and Garcia (2012), MH has been reported between 40% and 90% in ACP [4]. These findings concur with the high prevalence (76%) of MH in the present study. The complex pathophysiology of androgen deficiency in ACP has not been entirely elucidated. The presence of higher levels of circulating inflammatory mediators and/or concurrent oncological treatments have been shown in a combination of primary (i.e. related to testicular failure) and secondary (i.e. related to the hypothalamus–pituitary axis failure) hypogonadism [4]. The decline in testosterone levels observed in ACP may be negatively influenced by various factors such as other comorbidities [13], chronic opioid treatments [14], and changes in concentrations of sex-hormone-binding globulin [2].

Since the late 1980’s, physicians have agreed that MH is a non-specific consequence and a biomarker of chronic illness [13]. The current hypothesis to explain MH is based on the body’s adaptive response to the illness. During the recovery phase from illness, changes in homeostasis reflect a tendency to conserve energy, reduce aggressiveness, depresses libido and sexual activity. [13,15–17].

| Table 1. Patient characteristics, demographics, and ongoing treatments present at the assessment visit. |
|---------------------------------------------------------------|
| **Age (years) (mean ± SD)**             | **64.0 ± 11.5** |
| **Weight (kg) (mean ± SD)**             | **75.0 ± 17.0** |
| **Body mass (kg/m²) (mean ± SD)**       | **25.0 ± 5.3**  |
| **Tumour type (%)**                     | **NSCL 38.0**   |
|                                           | **GI 62.0**     |
| **Number of hypogonadic patients (%)**  | **76 (76%)**    |
| **Radiotherapy (%)**                    | **yes 19.0**    |
|                                           | **no 81.0**     |
| **Chemotherapy (%)**                    | **yes 39.0**    |
|                                           | **no 61.0**     |
Table 2. Multiple linear regression analysis comparing hypogonadic (free testosterone < 31.2 pmol/L) versus eugonadic patients.

| Variables | \( B \) | 95% CI         | \( p \)-value | \( n \) |
|-----------|---------|---------------|---------------|-------|
| White blood cells (10⁹/L) | 0.6 | −1.2; 2.40 | >0.20 | 100 |
| C-reactive protein (mg/L) | −0.6 | −25.3; 24.2 | >0.20 | = |
| Albumin (g/L) | −3.8 | −6.8; −0.8 | 0.01 | = |
| BMI (kg/m²) | −1.8 | −4.5; 0.7 | 0.15 | = |
| ESAS well-being (0–10 worse) | 0.3 | −0.9; 1.6 | >0.20 | = |
| ESAS weakness (0–10 worse) | 1.3 | −0.2; 2.8 | 0.09 | = |
| ESAS dyspnoea (0–10 worse) | −0.1 | −1.5; 1.2 | >0.20 | = |
| ESAS anorexia (0–10 worse) | 1.0 | −0.6; 2.5 | >0.20 | = |
| aPG-SGA Weight loss one month (%) | −0.06 | −2.7; 2.6 | >0.20 | = |
| aPG-SGA Weight loss six months (%) | 2.0 | −2.5; 6.5 | >0.20 | = |
| aPG-SGA box 4 (0–4 worse) | 0.6 | 0.1; 1.1 | 0.03 | = |
| aPG-SGA boxes 1–4 (0–36 worse) | 2.8 | −0.3; 5.9 | 0.08 | = |
| BFI Total (0–100 worse) | 16.7 | 2.0; 31.3 | 0.03 | = |
| MQoL Physical score (10–0 worse) | −2.2 | −4.0; −0.4 | 0.02 | = |
| MQoL Total score (10–0 worse) | −1.42 | −2.5; −0.3 | 0.01 | = |
| Handgrip average (lbs) | −11.7 | −20.4; −3.0 | <0.01 | = |
| Handgrip percentile | −11.2 | −20.6; −1.9 | 0.02 | = |
| Total fat mass* (kg) | −5.5 | −14.0; 3.0 | 0.20 | 48 |
| Percent fat* (%) | −4.3 | −12.3; 3.6 | >0.20 | = |
| Total lean mass* (kg) | −2.4 | −7.5; 2.72 | >0.20 | = |
| Percent lean* (%) | 4.6 | −2.7; 12.0 | >0.20 | = |
| Arms lean mass* (kg) | −0.8 | −1.4; −0.1 | 0.03 | = |
| Legs lean mass* (kg) | −1.1 | −3.1; 1.0 | >0.20 | = |
| Bone mineral content* (g) | −99.3 | −452.0; 253.4 | >0.20 | = |
| Bone mineral density* (g/cm²) | −0.02 | −0.1; 0.06 | >0.20 | = |

BMI = Body Mass Index, ESAS = Edmonton Symptom Assessment System, aPG-SGA = abridged Patient Generated Subjective Global Assessment, MQoL = McGill Quality of Life. * Measured by dual energy x-ray absorptiometry (DXA)

ACP present with symptoms of fatigue and cancer-related pain with the latter being typically treated with long-term opioid therapy [14]. Although cancer-related fatigue and pain were common symptoms in this clinical study, opioid therapy was not monitored. We have considered these facts as limitations of our study. Also because MH is a consequence of chemotherapy [18] and of the cancer per se [21], we did not report the percentage of those treated with or without opioids.

Handgrip strength as well as performance status (as measured by box 4 in the aPG-SGA) were clearly lower in the presence of androgen deficiency and this observation concurred with the presence of decreased lean mass in the arms and fatigue in hypogonadic patients. Kilgour et al (2010) have recently identified an association between muscle strength and muscle mass in ACP such that those who experienced greater fatigue had lower muscle mass and strength [5]. All of the above associations suggest that the lack of circulating testosterone could have a blunted anabolic impact on muscle morphology in cancer patients with MH. This hypothesis has been supported by eight clinical, randomised, double-blind, and placebo-controlled trials using testosterone but in a rather small cohort population of hypogonadic patients who were sarcopoenic with no diagnosis of cancer (https://clinicaltrials.gov/ct2/results?term=testosterone&cond=%22Sarcopenia%22). To date, only one clinical trial with testosterone administration has been conducted...
The results of this trial are sufficient to improve fatigue scores but not Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) quality of life measures [19]. An earlier retrospective study demonstrated a clear association between MH and a decrease in quality of life with poor survival [3]. These data are in agreement with the pivotal work of Traish et al (2011), who showed that a reversal of MH in ACP improves quality of life and survival [20].

In a Phase II clinical trial using Enobosarm, a selective androgen receptor modulator (SARM), Dobs et al (2011) reported an increase lean body mass when compared to the placebo [6]. In the same study, the patients on SARM were found to have a greater functional ability as measured by the stair climbing test [6] suggesting that the drug-induced increase in muscle mass may be related to the improvement in functional ability.

As mentioned above, we found an independent association between levels of free testosterone and albumin but no relationship between MH and C-reactive protein and white blood cell counts. The latter relationship is in contrast with other studies where androgen deficiency was clearly associated with high C-reactive protein levels [3, 8, 9]. There could be several factors to explain this discordance, including different clinical characteristics among the sample populations such as different cancer primaries, stages, and co-morbidities. Another possible explanation for lack of any relationship between MH and inflammation between our study and others could be related to the type of statistical analysis (e.g., univariate versus multivariate analyses) [7].

The multiple regression models showed independent correlations of MH with cancer-related fatigue (CRF), a trend towards self-reported weakness (p = 0.09) and quality of life in our patient population. However, multivariate analysis did not confirm the associations between the sense of well-being, dyspnoea, and anorexia with MH, which were found by Dev et al (2014) via univariate analysis. In this work, we conducted multivariate analyses taking into account the statistical influence of the covariates. There is a potential weakness in using univariate analysis when an independent variable (i.e., MH) may have more than one dependent variable influencing the statistical outcome. It is possible that the covariates used in our multiple regression analysis altered the relationship between MH and other potential correlates so much so that the significant univariate findings were lost. Fatigue has been frequently linked with androgen deficiency in malignant chronic conditions [10, 11]. This strong relationship between cancer-related fatigue (CRF) and hypogonadism indicates the need to rule out the presence of the latter condition whenever clinicians are looking for an improvement of CRF in ACP.

Our study is limited in its retrospective design and sample size. Furthermore, we only assessed androgen status via free testosterone levels, without measuring sex hormone binding globulin or luteinising hormone (LH) to better determine the causes of MH. The purpose of this paper was not to determine the cause of MH in advanced cancer, as if then would have required a vastly different design and sample size. In a recent review, Miner et al (2014) reported over 24 different aetiologies of MH, with ten primary, seven secondary, and seven mixed (primary and secondary) hypogonadism. However, the main goal of this study was not to establish the exact aetiology of hypogonadism (primary or secondary), but to better understand how the different factors are clinically relevant to MH in ACP.

Conclusions and future perspectives

In conclusion, MH appears to be highly prevalent and clinically significant in advanced cancer patients. Routine screening and treatment of this condition could allow for significant improvement in overall nutrition, function, and quality of life. The main concept emerging from this case series analysis, even if limited in the sample, is the importance to assess any degree of MH. In fact, other authors are investigating the role of MH in wasting diseases, such as sarcopenia and cachexia. In the current clinical practice, to better assess the symptoms of burden, depression, and fatigue scales of ACP, serum testosterone values should be included. Several questions remain to be answered. For example, does MH need to be present for muscle wasting to occur? Will the treatment of MH restore or help to maintain muscle mass, make patients stronger so that they can be more mobile, reduce fatigue levels, have a better QoL, and improve the other clinical correlates (e.g., improve albumin levels and reduce inflammation)?

This paper is part of an investigation that our laboratory is conducting on ACP. The next step will be to design a large population-based clinical trial in collaboration with other cancer centres to determine the importance of MH in the evolution of muscle wasting diseases.
Acknowledgments

The authors thank Dr Peter Chan and Dr Lodovico Balducci for having reviewed this manuscript. Dr Chan is medical director of the Male Reproductive Medicine Department and urological surgeon at McGill University Health Centre, Montreal, Canada. Dr Balducci is a geriatric oncologist at the Moffit, Tampa (Florida, USA), he received the inaugural BJ Kennedy Award for Scientific Excellence in Geriatric Oncology in 2007 from the American Society of Clinical Oncology (ASCO).

Author Contributions

Antonio Vigano conceived the project and had a primary role and responsibility for data collection and analysis, manuscript preparation, and submission.

Caroline Boulos participated in the preparation of the first version of the manuscript.

Robert Kilgour and Jose Morais provided their expertise for data analysis and manuscript preparation.

Domenico Fuoco, Jonathan Di Tomasso, and Manuel Borod participated in the preparation of the final manuscript and its submission.

Conflicts of Interest

The authors have no financial or other relations that could lead to conflict of interest.

Ethics

All subjects gave their written informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki. Ethical Approval was acquired from the Institutional Review Board of the McGill University Health Centre. The responsibility of the study was assigned to Dr Antonio Vigano as principal investigator and coordinator of the project. The project identification code is MN9614AV, and it was attributed to the McGill Nutrition and Performance Laboratory as the funding entity of the project.

References

1. Bhasin S, Cunningham GR and Hayes F (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab 91(6) 2536–59

2. Vigano A et al (2010) Male hypogonadism associated with advanced cancer: a systematic review Lancet Oncol 11(7) 679–84 DOI: 10.1016/S1470-2045(10)70021-8 PMID: 20541464

3. Dev R et al (2014) Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer Cancer 120(10) 1586–93 DOI: 10.1002/cncr.28619 PMID: 24577665 PMCID: 4046338

4. Burney BO and Garcia JM (2012) Hypogonadism in male cancer patients J Cachexia Sarcopenia Muscle 3(3) 149–55 DOI: 10.1007/s13539-012-0065-7 PMID: 22528986 PMCID: 3424192

5. Kilgour RD et al (2010) Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer J Cachexia Sarcopenia Muscle 1(2) 177–185 DOI: 10.1007/s13539-010-0016-0
6. Dobs AS et al (2013) Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial Lancet Oncol 14(4) 335–45 DOI: 10.1016/S1470-2045(13)70055-X PMID: 23499390

7. Gagnon B et al (2013) The effect of severe androgen deficiency on physical function in male patients with cancer J Pain Symptom Manage 45(5) 892–900 DOI: 10.1016/j.jpainsymman.2012.05.010

8. Kaplan SA et al (2010) Elevated high sensitivity C-reactive protein levels in aging men with low testosterone Aging Male 13(2) 108–12 DOI: 10.3109/13685530903440424

9. Del Fabbro E et al (2010) Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report J Pain Symptom Manage 39(6) 1016–24 DOI: 10.1016/j.jpainsymman.2009.09.021 PMID: 20457506

10. Strasser F et al (2006) The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer Cancer 107(12) 2949–57 DOI: 10.1002/cncr.22339 PMID: 17103445

11. Greenfield DM et al (2010) Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study Cancer 116(6)1592–601 DOI: 10.1002/cncr.24898 PMID: 20186765

12. Morley JE (2000) Andropause, testosterone therapy, and quality of life in aging men Cleve Clin J Med 67(12) 880–2 DOI: 10.3949/ccjm.67.12.880 PMID: 11127982

13. Semple CG, Gray CE and Beastall GH (1987) Male hypogonadism – A non-specific consequence of illness Q J Med 63(243) 601–7

14. Daniell HW (2007) Opioid-induced androgen deficiency discussion in opioid contracts Am J Med 120(9) e21 DOI: 10.1016/j.amjmed.2006.05.027 PMID: 17765033

15. Seftel A (2006) Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis Int J Impot Res 18(3) 223–8 DOI: 10.1038/si.ijir.3901365

16. Kalyani RR, Gavini S and Dobs AS (2007) Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am 36(2) 333–48 DOI: 10.1016/j.ecl.2007.03.014 PMID: 17543722

17. Miner MM and Sadovsky R (2007) Evolving issues in male hypogonadism: evaluation, management, and related comorbidities Cleve Clin J Med 74(Suppl 3) S38–46 DOI: 10.3949/ccjm.74.SUppl_3.S38 PMID: 17549824

18. Howell SJ et al (2001) Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy Clin Endocrinol (Oxf) 55(3) 315–24 DOI: 10.1046/j.1365-2265.2001.01297.x

19. Del Fabbro E et al (2013) Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial Support Care Cancer 21(9) 2599–607 DOI: 10.1007/s00520-013-1832-5 PMID: 23653013

20. Traish AM et al (2011) Testosterone deficiency Am J Med 124(7) 578–87 DOI: 10.1016/j.amjmed.2010.12.027 PMID: 21683825

21. Miner M, Barkin J and Rosenberg MT (2014) Testosterone deficiency: myth, facts, and controversy Can J Urol 21(Suppl 2) 39–54 PMID: 24978631

22. Mendoza T et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory Cancer 85(5) 1186–96 DOI: 10.1002/(SICI)1097-0142(19990501)85:5<1186::AID-CNCR24&gt;3.0.CO;2-N PMID: 10091805

23. Cohen SR et al (1996) Existential well-being is an important determinant of quality of life. Evidence from the McGill Quality of Life Questionnaire Cancer 77(3) 576–86 DOI: 10.1002/(SICI)1097-0142(19960201)77:3&lt;576::AID-CNCR22&gt;3.0.CO;2-0 PMID: 8630968